News
Burrill & Company Leads $12.9 Million Series E Round In WhiteGlove Health April 16, 2012 | Press Release
Burrill & Company Leads $16.5 Million Round in WaveTec Vision to Commercialize Its Cataract Surgery Breakthrough April 16, 2012 | Press Release
Burrill & Company Leads ADMA Biologics’ $17.5 Million Private Placement April 15, 2012 | Press Release
See all NewsInternational

Thomas Gerlach
DirectorLatin America
Thomas Gerlach joined Burrill & Company in 2012 after nearly 20 years in the pharmaceutical industry in different positions within multinational companies where he was involved in drug development, brand management. From 2002 to 2010 he served as general manager of Actelion Pharmaceuticals do Brasil, the Brazilian subsidiary of Actelion. There he laid the foundation for the company’s Latin American operations. He originally joined Actelion as a project manager in Switzerland in 2000. Prior to that, Mr. Gerlach held positions with Novartis, Knoll AG, and BASF Pharma.He has been a visiting scholar at Michigan State University where he worked on research projects in the field of retinoids. He holds a Ph.D. in Pathobiochemistry from and a degree in Chemistry (Staatsexamen) from the University of Mainz, Germany, and a masters in biology from the University of Mainz. He is fluent in German, English, Portuguese, and has some understanding of Spanish.

